In both complete carboplatin responders and partial responders, PDX models with lower PLK2 expression had a better response to volasertib, which induced tumor cytostasis (BCM-0002 vs. BCM-7482, BCM-2665 vs. BCM-15003; Fig. 5A, C, E, G, and I; Supplementary Fig. S10 and S11). This evidence concerns the gene PLK2 and neoplasm.